scispace - formally typeset
M

Maureen E. Murphy

Researcher at Wistar Institute

Publications -  161
Citations -  30688

Maureen E. Murphy is an academic researcher from Wistar Institute. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 52, co-authored 148 publications receiving 26024 citations. Previous affiliations of Maureen E. Murphy include Princeton University & Stanford University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease

Brent R. Stockwell, +27 more
- 05 Oct 2017 - 
TL;DR: The mechanisms underlying ferroptosis are reviewed, connections to other areas of biology and medicine are highlighted, and tools and guidelines for studying this emerging form of regulated cell death are recommended.
Journal ArticleDOI

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Charles L. Vogel, +12 more
- 01 Feb 2002 - 
TL;DR: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
Journal ArticleDOI

Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

Andrew D. Seidman, +8 more
- 01 Mar 2002 - 
TL;DR: Trastuzumab is associated with an increased risk of cardiac dysfunction, which is greatest in patients receiving concurrent anthracyclines, and in most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzUMab.